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of an anti-hypertensive medication combination and compared with current care 
(23.9% BP control rate). 100,000 hypertensive simulated individuals were modeled 
over a 10 year time horizon. Outcomes of major adverse cardiovascular events; stroke, 
myocardial infarction (MI) and CV death were reported. Direct health care costs of 
strokes and MIs were derived from official Russian statistics and price lists. Results: 
To achieve SBP control rates of 30%, 40%, 50%, and 60%, adherence rates to the anti- 
hypertensive treatment program were 11.1%, 29.4%, 47.6%, and 65.9% respectively. CV 
death relative risk reductions were 5.0%, 13.2%, 21.4%, and 29.6%, respectively. For the 
current estimated 43,855,000 person Russian hypertensive population, each control 
rate scenario resulted in an absolute reduction of 398,097, 1,050,715, 1,703,334 and 
2,355,952 CV deaths, and a reduction of 458,781, 1,210,881, 1,962,981, and 2,715,081 
stroke/MI diagnoses. Averted direct costs from current care (225,781) were 12,834, 
33,873, 54,913 and 75,952 million Rubles, respectively. ConClusions: Our simulation 
implies that a clinically significant number of CV events in the Russian hypertensive 
population may be prevented by achieving BP control through an antihypertensive 
drug combination. Averted costs may be re-allocated to strengthen evidence-based, 
preventive interventions.
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objeCtives: To describe UK patients with acute coronary syndrome (ACS) who 
receive percutaneous coronary intervention (PCI) or are medically managed only 
(MM) and evaluate factors affecting approaches to treatment. Methods: Patients 
registered with a general practice participating in the Clinical Practice Research 
Datalink (CPRD) with Hospital Episode Statistics (HES)-linked data were included 
if they had an ACS-related hospitalization (January 2008-December 2009). Logistic 
regression analyses were used to assess what characteristics at ACS-related hospi-
talization date were associated with PCI or MM classified at 30-days post-hospital-
isation date (30DHD). Results: A total of 10,753 ACS patients were identified (60% 
male, 67% aged ≥ 65, 81% had NSTEMI or UA at index date); 30DHD, 74% were MM 
and 26% had PCI. Factors associated with receiving PCI were STEMI at hospitalization 
(OR 3.73, 95% CI 3.30, 4.22); patients with previous PCI pre-hospitalization (OR 1.29, CI 
1.07, 1.55) and current smokers (OR 1.16, CI 1.02, 1.32). Patients less likely to receive 
PCI included women (OR 0.67, CI 0.60, 0.75), those with previous ACS hospitaliza-
tion (OR 0.69, CI 0.59, 0.80), those prescribed: statins 12 months pre-hospitalization 
date (OR 0.75, CI 0.67, 0.85), diuretics (OR 0.72, CI 0.61, 0.85), ACE inhibitors (OR 
0.84, CI 0.75, 0.95), proton pump inhibitors (OR 0.86, CI 0.77, 0.96), those previously 
diagnosed with congestive heart disease (OR 0.54, CI 0.42, 0.71), atrial fibrillation 
(OR 0.67, CI 0.54, 0.83), stroke/TIA (OR 0.77, CI 0.63, 0.93) or renal disease (OR 0.82, 
CI 0.71, 0.95). Age and BMI were significant as continuous variables with non-linear 
effects. ConClusions: This is the first large-scale UK study using real-world data 
to assess socio-demographic and clinical predictors for PCI in ACS, and indicates 
that NSTE-ACS patients and those with comorbidities are more likely to be MM. This 
will be discussed in light of current treatment of STEMI and NSTE-ACS in the EU.
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objeCtives: To analyze the current state and the trends of pharmacoeconomic 
research in cardiology in Russia. Methods: We have reviewed all main databases 
of scientific publications (PubMed, eLibrary.ru etc.) as well as individual journals, 
conference abstracts and web-sites for the period 2007–2013. Results: It was found 
that cardiology becomes one of the most popular topics for pharmacoeconomists, 
partly because of its significance for public health and the growing amount of state 
funding for the prevention of CVD in recent years. Cardiovascular problems make up 
16-25% of congress abstracts and 26% of applications for Da.Signa, the only award in 
pharmacoeconomics in Russia. Most publications in our analysis dealt with arterial 
hypertension (44%), coronary heart disease (16%) and chronic heart failure (7%). A 
wide range of original and generic drugs were included into these researches, how-
ever in most cases there was a prevalence of cost-efficiency analysis and modeling 
methods based on the results of non-Russian clinical trials and meta-analyses. 
Overwhelming majority of the results were published in Russian and therefore are 
not available for the non-Russian-speaking reader. ConClusions: During the last 
five years, a great number of pharmacoeconomic research in cardiology have been 
performed and published. However, there is a need of clinical trials that would con-
sider the Russian specifics and health care standards. Pharmacoeconomic analysis 
should become an integral part of clinical trials, especially in case of drug therapy 
of myocardial infarction, stroke and other conditions, where the differences exist 
between the Russian and foreign practice. Some of the analyzed publications should 
be updated because of the recent changes in health care standards.
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objeCtives: To analyze the volume-outcome relationship for patients with intact 
abdominal aortic aneurysm (AAA) and hip fracture (HIP) and define hypothetical 
minimum volume standards to assess changes in access. Methods: The analy-
sis is based on administrative data coming from the German system of diagnosis 
related groups of about 18.6 million hospital cases of 1780 German hospitals for the 
year 2007. The data includes detailed information on patient characteristics used for 
Re-hospitalisations were taken into account if they occurred after one month fol-
lowing inclusion and regardless of the location of the hospital at the national level. 
Alternatively, ‘all’ re-hospitalisations rates regardless the related diagnosis were also 
assessed. Inpatient costs were valued based on reference tariffs according to French 
National Social Health Payer perspective. Results: Around 1750 patients were fol-
lowed per cohort across the four hospitals starting from 2009, 2010 and 2011. One-
year re-hospitalisations rates for ST and TI ranged from 2.9% to 7.1%. The median 
time to re-hospitalisation ranged between 1.5 to 9.3 months. Two-year re-hospitali-
sations rates for ST and TI ranged from 4.5% to 10.4%. Two-year re-hospitalisations 
rates regardless of related diagnosis in acute and/or rehabilitative settings ranged 
between 45.5% to 65.1%. Mean costs (+/-SD) per inpatient stay for ST and TI were 
4’645€ (+/-3’821) in acute setting (2013 EUR). When excluding TI, mean costs were 
5’293€ +/-4’225€ . Hospitalization costs varied depending on sub-type of stroke, sever-
ity, co-morbidities and also year of costing. ConClusions: Such short term data 
on recurrence rates and inpatient costs might be useful when estimating potential 
benefits of any secondary prevention intervention aiming at reducing stroke relapses.
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objeCtives: We examined the economic consequences of generic switching within 
the statin market for public plans in Canada between 2000 and 2012. Methods: 
We extracted data (number of units, costs, and claims) for all statins reimbursed 
by Canadian public drug plans for the period 2000-2012 (sources: IMS Brogan and 
Canadian Institute for Health Information). Results: Public plans paid $11.2 BN to 
reimburse statins for 2 MM patients between 2000 and 2012. The annual cost of reim-
bursing statins peaked at $1.3 BN in 2009. Generic atorvastatin was listed by public 
plans in 2010, and the proportion of statin reimbursement attributable to generics 
increased from 18% in 2009 to 75% in 2012, reflecting a 76% increase in generic switch-
ing. During the same period, the unit cost of brands and generics fell by 25% and 49%, 
respectively. The combined effect of increased generic switching and lower unit costs 
resulted in a 55% decrease in the total cost of statins, from $1.3 BN in 2009 to $582 MM 
in 2012. Annual savings attributable to generic switching increased 10-fold between 
2000 and 2012, from $7 to $709 MM. The efficiency at which potential savings has been 
captured through generic switching increased from 8% to 74% from 2000 to 2012; we 
project that this will generate savings of ~$800 MM annually through 2015. Increasing 
generic switching to 100% could generate up to an average of $135 MM annually in 
additional savings ConClusions: Although substantial savings have been gener-
ated by generic switching within the statin class, increasing generic switching could 
generate additional savings. One strategy to capture these additional savings would 
be disinvestment: if branded statins were de-listed from public plans if a generic ver-
sion were available, this would increase generic switching, increase the efficiency at 
which potential savings are captured, and increase total savings.
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objeCtives: To estimate the Disability Adjusted Life-Years (DALY) attributable to 
Atrial Fibrillation (AF) during 2010 in Portugal, including both AF and AF related 
stroke. Methods: The analysis requires two types of data. The first is an extended 
set of epidemiological data, which resulted from a compilation of the prevalence and 
mortality data for AF and for stroke in Portugal. For the distribution of mortality by 
age, gender and cause of death the WHO Europe mortality database was used. The 
analysis also uses the results of FAMA, a study of the prevalence of AF in Portugal. 
Incidence rates were estimated from a review of the international literature. The 
second type of data concerns the relative risk (RR) of stroke for patients with AF. 
RR values by age group from the Framingham Study were used. Disability weights 
were taken from the Global Burden of Disease 2010. Results: A total of 3863 deaths 
in Portugal in 2010 were related to AF, with 813 having AF listed as cause of death 
and the remaining 3.050 being stroke deaths attributable to AF. The AF attributable 
deaths are roughly 3.6% of total deaths in the country. The estimate total DALYs 
was 9.814 (2.251 for AF listed as the cause of death and 7.563 for stroke as cause of 
death attributed to AF). ConClusions: AF is an important cause of disease burden 
in Portugal. As reference, AF DALYs are roughly twice the estimated DALYs for skin 
cancer. AF should receive adequate attention from policy makers.
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objeCtives: Russia faces a high burden of cardiovascular (CV) disease. Prevalence 
of all CV risk factors, especially hypertension, is high. Elevated blood pressure (BP) 
is generally poorly controlled, and medication usage is suboptimal. With a disease 
model simulation we assessed the impact of improved systolic blood pressure (SBP) 
control on the number and costs of CV events potentially averted in the hypertensive 
Russian population. Methods: The Archimedes Model, a detailed computer model 
of human physiology, disease progression, and health care delivery was adapted to 
the Russian setting. Intervention scenarios of achieving SBP control rates (defined as 
SBP < 140) of 30%, 40%, 50%, and 60% were simulated by modifying adherence rates 
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level. The development of the performance measures over time may be attributed 
to changes in organization and management of the system. Methods: As routine 
data the ATHIS 2006/2007 (a standardized health interview survey), the cause of 
death registry 2006 and 2007, the hospital discharge datasets from the Austrian 
DRG system 2006/2007 (KDok/DLD) and diagnoses for the outpatient sector derived 
from pharmaceutical claims data 2006/2007 (ATC→ICD) - are used to describe the 
burden of disease regarding Ischemic Heart Disease (ICD9 410–414) with differ-
ent regional granularity. Methods and results are compared with epidemiological 
data extracted from a literature search on this topic. To explore the similarity 
of the results of these different methods of measurement a systematic review of 
regional correlation is being elaborated. Correlations pointing to a high analogy of 
the findings in spite of the differences in dimensions measured on the one hand and 
contra intuitive correlations on the other hand were further explored. Results: The 
review of regional correlation indicates promising close links between the burden 
of disease derived from ATC→ICD, ATHIS and cause of death registry data. Hospital 
discharge data, however, show some contra-intuitive relations towards the other 
data sets. ConClusions: The use of routine data yields promising opportunities 
for monitoring the Austrian health care system in a timely and comprehensible 
way. It enables different aggregation levels regarding regions and periods and leads 
the way to further research addressing underlying causes for the observed regional 
variation. The methodology can be transferred to other areas of diseases.
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objeCtives: Abdominal Aorta Aneurysms (AAAs) refers to distension of the abdominal 
aorta. It is a common disease among 65+ year old people with increasing importance due 
to overageing of the population. Currently, AAAs in Austria are only incidentally detected 
and due to its asymptomatic course often overlooked therefore the impact of an organ-
ized screening program in Austria was evaluated. Methods: An agent based simulation 
model for Austria’s population was developed. Each agent represents a person which 
has an individual development of its aorta depending on age, sex, and smoking habits. 
Identification of risk factors and parameterization of the model was performed in the 
IFEDH project (FFG grant number 827347). The observed persons are 65 years old at 
simulation start and the observed time horizon is 20 years. The chosen screening strat-
egy which is compared to current practice corresponds to the EUnetHTA scheme with 
an assumed 40% participation. Results: Events like ruptures, deaths or treatment are 
recorded and accumulated over the whole simulation time. Additionally, because many 
figures of the model depend on probabilities, the point in time when patients benefit 
from the intervention with 95% probability is calculated. Ruptures are reduced from 786 
to 531, death cases from 571 to 433 whereas the costs per life year gained are about 7500 
€ . Significant differences can be observed after about four years. Although incidence 
is much higher among men, it is remarkable that screening is more cost-effective for 
women due to higher risk of rupture and life expectancy. ConClusions: The agent 
based simulation model allows detailed analysis of groups with specific properties, e.g. 
smokers, other age groups and different screening strategies. It also allows decision 
makers to estimate when the impact of the intervention, in this case organized screen-
ing, can be observed or measured within the real population.
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objeCtives: To estimate the potential added value of an ultrasound-fluoroscopy 
fusion technology and to support product development and marketing positioning 
of the technology in interventional cardiology, using a combination of research 
methods. Methods: Stakeholder analysis was carried out to determine the profes-
sionals involved in the adoption process. Literature search indicated which proce-
dures could benefit most from the imaging technology. Subsequently, the current 
workflow and associated resource use of those procedures was compared with the 
expected workflow after potential technology adoption. Decision criteria to adopt 
the new imaging technology were evaluated with the analytical hierarchy process 
(AHP). Finally, a value based pricing approach was used to estimate the value of the 
technology to specific types of hospitals. Results: Intervention cardiologists were 
identified as key stakeholders in the adoption of technology. The AHP showed that 
reduction in complication rates is the most important criterion for adopting a new 
imaging technology, whereas the purchase price seemed less important. Various 
procedures could benefit from the new technology, as this may shorten procedural 
times and facilitate communication between intervention cardiologists and imag-
ing professionals. Value based pricing analysis showed that cost savings could be 
expected as a result of reduced procedure times, especially in centers of expertise 
with medium to high procedure volumes. ConClusions: The ultrasound-fluoros-
copy fusion technology can provide added value in specific cardiac interventions, 
especially in hospitals with medium to high procedure volumes. Early assessment 
of potential added value and adoption criteria timely and effectively supported the 
product development phase. It informed various decision makers on the factors 
influencing the expected value of and uncertainties surrounding a future adoption 
of the technology.
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risk-adjustment. Furthermore, we have a ZIP-code for each patient and the exact 
address for every hospital. Addresses of hospitals and the centroids of all German ZIP 
codes were geo-coded. For the empirical analysis, we use multiple logistic regression 
analysis. We supplement our analysis by showing changes in access to hospitals if a 
minimum volume standard is introduced. Results: Patients with hip fracture who 
are treated in hospitals with less than 58 cases per year have an average probability of 
death of 5.1 % compared to an average mortality of 3.1 % for patients who are treated 
in hospitals with more than 151 cases. For patients with AAA the case volume effect 
is lower. However, compared to patients treated in hospitals with less than 15 cases 
per year, the average probability of death for patients treated in hospitals with more 
than 68 cases is 1.0 percentage points less. We show that minimum volume standards 
seem possible without compromising overall access. ConClusions: The estima-
tion results suggest that around 380 deaths could have been presumably avoided, 
if around 20,000 patients in the smallest hospitals would have been treated in the 
largest hospitals instead. Furthermore, we show that minimum volume standards 
do not compromise overall access measured in travel times. However, to ensure an 
adequate access in all areas, a few “sole providers” in some regions seem necessary.
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objeCtives: Drug prescriptions recorded in health care administrative databases 
(HADs) can be an indicator of moderate health outcomes (undetectable through hos-
pitalization or death registries) correlated to particulate matter (PM) exposure. This 
study is aimed at assessing the short-term effect of PM10 exposure on the risk of car-
diorespiratory drug prescription in Lombardy, a region in northern Italy. Methods: 
For each resident in seven cities of Lombardy, we identified all prescriptions of 
selected respiratory, cardiovascular and antidiabetic treatments recorded during 
2005-2006 in data warehouse DENALI, which gathers HADs of Lombardy health 
system. The Regional Environmental Protection Agency of Lombardy provided time-
series of daily mean PM10 concentration. We applied a time-stratified case-crossover 
design matched by day of week and fitted separate Cox proportional hazard models 
for each respiratory and cardiovascular treatment. Confounding was accounted for 
using a method, which we developed, based on the time-series of prescription of 
antidiabetics. Analyses were replicated for delayed effects of PM up to 6 days and 
for warm and cold season. Results: The study area counted 470,300 residents, 
requiring 655,805 prescriptions. Mean PM10 concentration was 48µg/m
3 (SD 32µg/
m3). Overall, we estimated that rises in PM10 concentration were associated with 
an immediate increment in the risk of prescription of inhalant adrenergics (0.32% 
for increments of 10µg/m3 in PM10 concentration; 95%CI:0.00,0.65), antiarrhythmics 
(0.52%; 95%CI:0.16,0.87) and nitrates (0.51%; 95%CI:0.27,0.76). Increased PM10 expo-
sure was also positively associated with the prescription of inhalant glucocorticoids 
during the warm season and of inhalant adrenergics, antiarrhythmics and nitrates 
during the cold season. ConClusions: The significant association that we detected 
between PM concentration and drug prescriptions suggests that PM exposure may 
impact public health not only through severe but also through moderate adverse 
events. Further investigation is needed and given the usual difficulty retrieving 
information on moderate outcomes, HADs represent a valuable data source.
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objeCtives: To estimate the impact of hypercholesterolemia (HYP) on population 
health in Portugal. Methods: We estimate the Disability Adjusted Life-Years (DALY) 
attributable to HYP in 2010. The DALY include both years lost to premature death and 
years lost to disability. HYP is a risk factor for Acute Myocardial Infarction (ICD 9 410), 
other Coronary Heart Diseases (ICD 9 411-414) and for Ischemic Stroke (ICD 9 433-434). 
In order to estimate the attributable fractions to HYP of the diseases considered a 
microsimulation approach was used by using Framingham equations on data from 
individual observations in the VALSIM database. A total cholesterol equal to the mean 
for observations above 200 mg/dL was imputed to all individuals under statin treat-
ment. In a counterfactual scenario HYP was eliminated (reducing total cholesterol to 
200 mg/dL and increasing HDL to 40 mg/dL in all cases with HYP). The resulting pro-
portional change in the probability of events was taken as the HYP attributable fraction 
of the diseases studied. Results: In Portugal the prevalence of HYP in 2010 was esti-
mated at 55,5% of the population over 18 (56,7% male and 54,5% female). In 2010 there 
were 1689 deaths attributable to HYP. This number can be broken down by gender (640 
males and 1050 females) or by disease (481 from Acute Myocardial Infarction, 235 from 
other ischemic heart disease and 974 from ischemic stroke). DALY for premature death 
were estimated at 7263, and DALY for disability at 8239. Of the total 15502 DALY attrib-
utable to HYP 6132 were for ischemic stroke and 9369 for coronary disease. Gender 
decomposition of this total was 8012 for males and 7489 for females. ConClusions: 
The analysis suggests that HYP is an important cause of disease burden in Portugal 
and that it should remain a major target for health policy interventions.
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objeCtives: Monitoring the performance of the health care system requires 
timely and robust information highlighting the burden of disease on a regional 
